A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours

被引：0
|
作者：
Hyung-Don Kim
Changhoon Yoo
Min-Hee Ryu
Yoon-Koo Kang
机构：
[1] University of Ulsan College of Medicine,Department of Oncology, Asan Medical Center
来源：
British Journal of Cancer | 2023年 / 129卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：275 / 282
页数：7
相关论文
共 50 条
  • [21] A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Cresti, N.
    Jodrell, D.
    Arkenau, T.
    Forster, M.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Plummer, R.
    Spicer, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S160 - S161
  • [22] A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update.
    van Oosterom, A
    Reichardt, P
    Blay, JY
    Dumez, H
    Fletcher, J
    Debiec-Rychter, M
    Shand, N
    Drimitrijevic, S
    Yap, A
    Demetri, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 824S - 824S
  • [23] A phase I and pharmacological study of intermittent dosing of PKI166, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally to patients with advanced cancer.
    Hoekstra, R
    Dumez, H
    Eskens, F
    Sizer, K
    Cohen, P
    Ravera, G
    Verweij, J
    Van Oosterom, A
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3771S - 3771S
  • [24] Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing Multiple sclerosis: a randomised, placebo-controlled, phase 2 study
    Montalban, X.
    Arnold, D.
    Weber, M.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E.
    Syed, S.
    Dangond, F.
    Wolinsky, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 32 - 32
  • [25] Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'
    Schoffski, Patrick
    Mir, Olivier
    Kasper, Bernd
    Papai, Zsuzsanna
    Blay, Jean-Yves
    Italiano, Antoine
    Benson, Charlotte
    Kopeckova, Katerina
    Ali, Nasim
    Dileo, Palma
    LeCesne, Axel
    Menge, Franka
    Cousin, Sophie
    Wardelmann, Eva
    Wozniak, Agnieszka
    Marreaud, Sandrine
    Litiere, Saskia
    Zaffaroni, Facundo
    Nzokirantevye, Axelle
    Bempt, Isabelle Vanden
    Gelderblom, Hans
    EUROPEAN JOURNAL OF CANCER, 2020, 134 : 62 - 74
  • [26] A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
    Beckermann, Kathryn E.
    Bestvina, Christine M.
    El Osta, Badi
    Sanborn, Rachel E.
    Borghaei, Hossein
    Lammers, Philip Edward
    Selvaggi, Giovanni
    Whisenant, Jennifer G.
    Heimann-Nichols, Ellen
    Berry, Lynne
    Hsu, Chih-Yuan
    Shyr, Yu
    Horn, Leora
    Wakelee, Heather
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [27] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours.
    Shaw, H.
    Plummer, R.
    Vidal, L.
    Perrett, R.
    Pilkington, M.
    Temple, G.
    Fong, P.
    Amelsberg, A.
    Calvert, H.
    De Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 127S - 127S
  • [28] Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Spicer, J.
    Baird, R.
    Suder, A.
    Cresti, N.
    Corbacho, J. Garcia
    Hogarth, L.
    Frenkel, E.
    Matsumoto, S.
    Kawabata, I.
    Donaldson, K.
    Posner, J.
    Sarker, D.
    Jodrell, D.
    Plummer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (02) : 137 - 145
  • [29] Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
    George, Suzanne
    Demetri, George D.
    Lydon, Nick
    Kadambi, Vivek
    Christo, Jessica
    Johnson, Debbie
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS483 - TPS483
  • [30] Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors
    Eskens, F. A. L. M.
    de Jonge, M. J. A.
    Van Doorn, L.
    Isoe, T.
    Hayashi, K.
    Hussain, S.
    Ekman, L.
    Burger, H.
    Verweij, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 16 - 16
12345